GLP1

Authorities have unearthed a racket involving the manufacturing and sale of "fake" Mounjaro (tirzepatide) injections and arrested two persons here in this connection, an official said on Monday. A nationwide alert has been issued to detect the counterfeit injections and an investigation is underway to unravel the entire network, including all those involved in this racket, Drug Control Officer Amandeep Chauhan said. He said a Health Department team raided a residential society in Sector 62 on Monday and arrested two people, including the key accused. The accused were importing raw drugs from China and manufacturing counterfeit injections of Mounjaro. The entire racket was being run from a flat in the society. The accused supplied these illegal injections through the B2B portal Indiamart, the officer alleged. Mounjarois a weekly injectable medication for type 2 diabetesthat significantly improves blood sugar control and aids weight loss. "We received information about a fake inject

Global drugmakers are prioritising China and Japan for GLP-1 investments due to stronger pricing power and adoption, while India remains a large but price-sensitive market with slower premium uptake

Hetero plans to launch the drug in India in ‌April, focusing on building market share overseas to begin with, Managing Director Vamsi Krishna Bandi said

Doctors caution against cosmetic misuse of GLP-1 drugs as cheaper generics boost access, raising risks of unsupervised use and short-term weight-loss trends

Generic semaglutide surge dents Mounjaro sales, reshaping India's fast-growing GLP-1 diabetes and obesity drug market

Mounjaro sales in March dropped to ₹114 crore ($12.3 million) in March from ₹135 crore a month earlier, Pharmarack data show

A large-scale study finds semaglutide may lower the risk of depression and anxiety, adding an unexpected mental health dimension to its known physical health benefits

Company plans to leverage capacity gaps and pricing dynamics in insulin as global pharma majors shift focus to GLP-1 therapies amid rising diabetes burden

Experts explain the science behind hair loss reports, noting that the shedding is usually temporary and linked to how the body responds to rapid weight loss

Regulators have been asked to track adverse events as India tightens oversight on popular obesity drugs amid rising demand and concerns over misuse and misleading promotions

To prevent unauthorised sale, unsupervised use, and other malpractices, the Drug Controller of India has intensified its regulatory surveillance, warning that the drugs can lead to serious side effect

Drugmaker cuts prices of injectable semaglutide brands to expand access in India, but says no similar price reduction is planned for oral semaglutide brand Rybelsus

A week before semaglutide's patent expiry, the CDSCO issued an advisory warning pharma companies against promoting prescription weight-loss drugs, banned by law

India's 'cheap Ozempic moment' is here as semaglutide prices fall sharply, but doctors warn against misuse and stress careful evaluation before using these weight-loss injections

As cheaper GLP-1 weight-loss drugs flood India after patent expiry, the government has intensified surveillance to curb illegal sales, misleading promotion, and unsafe use without medical supervision

A large real-world study finds patients stopping semaglutide or tirzepatide may not regain as much weight as expected, aided by treatment switches, restarts, and lifestyle support

A Lancet report warns counterfeit weight-loss injections like Ozempic and Mounjaro are spreading globally, driven by high demand and prices, raising serious risks for patients

Drug regulator warns pharma companies that obesity awareness drives linked to GLP-1 drugs could amount to misleading promotion of prescription medicines

Indian CDMOs are expanding manufacturing capacity and investing in advanced technologies as global pharma companies increasingly outsource complex drug development and manufacturing work

Patients on GLP-1 drugs report losing cravings for addictions, ranging from opioids to gambling, prompting researchers to examine whether these diabetes and obesity medicines can curb addiction